• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tactile Medical Announces New Appointments to Board of Directors

    1/5/22 4:05:00 PM ET
    $JNJ
    $ORCL
    $PHG
    $TCMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $JNJ alert in real time by email

    MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the appointment of Valerie L. Asbury and D. Brent Shafer to the Company's Board of Directors ("Board"), effective January 5, 2022. Ms. Asbury will serve as a member of both the Audit Committee and the Compliance & Reimbursement Committee. Mr. Shafer will serve as a member of the Audit Committee, the Compensation & Organization Committee, and the Nominating & Corporate Governance Committee. Three long-standing directors will be retiring from the Board ahead of the May shareholder meeting: Peter Soderberg, Richard Nigon and Kevin Roche.

    "We are extremely pleased to welcome Valerie and Brent to our Board; both experienced leaders, adding depth of expertise in the treatment of chronically ill patients and channels to access and support them," said Bill Burke, Chairman of the Board of Tactile Medical. "I would also like to extend my sincere gratitude to Peter, Dick and Kevin for their dedicated years of service. Their counsel and oversight played an important role in helping Tactile Medical become a successful company, eclipsing $200 million in annual revenue."

    Since 2018, Valerie Asbury has served as the President and CEO of LifeScan, a global leader in blood glucose monitoring, serving more than 20 million people with diabetes. Ms. Asbury previously held a series of leadership roles within Johnson & Johnson (NYSE:JNJ) for over 20 years from 1998 to 2018, including executive sales and general management positions. Her most recent position at Johnson & Johnson was Global President of Diabetes Solutions from 2013 to 2018, including the Global LifeScan subsidiary until its sale in October 2018 to Platinum Equity, a leading private investment firm. She holds a Bachelor of Science in Nursing from Vanderbilt University.

    Brent Shafer most recently served as Chairman and CEO of Cerner Corporation from 2018 until September 2021, a global healthcare technology company that was acquired by Oracle Corporation (NYSE:ORCL) in December 2021. Prior to Cerner, Mr. Shafer was Chief Executive Officer of Philips North America, a health technology company and the North American division of Koninklijke Philips N.V. (("Philips", NYSE:PHG, AEX: PHIA)), from 2014 to 2018. Mr. Shafer also served as Chief Executive Officer of the global Philips' Home Healthcare Solutions business from 2010 until 2014. Mr. Shafer previously held a series of leadership roles at Philips, Hill Rom and GE Healthcare. He holds a Bachelor of Science from the University of Utah.

    About Tactile Medical

    Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.  



    Investor Inquiries:
    Mike Piccinino, CFA
    Managing Director
    ICR Westwicke
    [email protected]

    Primary Logo

    Get the next $JNJ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $ORCL
    $PHG
    $TCMD

    CompanyDatePrice TargetRatingAnalyst
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    12/17/2025Sector Perform
    RBC Capital Mkts
    Oracle Corporation
    $ORCL
    12/11/2025$355.00 → $270.00Outperform
    BMO Capital Markets
    Oracle Corporation
    $ORCL
    12/3/2025$280.00Overweight
    Wells Fargo
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    Oracle Corporation
    $ORCL
    11/10/2025Buy → Hold
    Erste Group
    Tactile Systems Technology Inc.
    $TCMD
    11/4/2025$28.00Neutral → Buy
    BTIG Research
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    Oracle Corporation
    $ORCL
    10/13/2025$345.00 → $355.00Outperform
    BMO Capital Markets
    More analyst ratings

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Philips

    RBC Capital Mkts initiated coverage of Philips with a rating of Sector Perform

    12/17/25 9:26:42 AM ET
    $PHG
    Medical Electronics
    Health Care

    BMO Capital Markets reiterated coverage on Oracle with a new price target

    BMO Capital Markets reiterated coverage of Oracle with a rating of Outperform and set a new price target of $270.00 from $355.00 previously

    12/11/25 8:00:07 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Wells Fargo initiated coverage on Oracle with a new price target

    Wells Fargo initiated coverage of Oracle with a rating of Overweight and set a new price target of $280.00

    12/3/25 8:40:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Woods Eugene A.

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/11/25 5:02:15 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hewson Marillyn A

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/11/25 4:59:44 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pinto Daniel E

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/11/25 4:58:40 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

    - TRUFILL n-BCA is now indicated for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and Chronic Subdural Hematoma (cSDH) as an adjunct to surgery.- Approval builds on a trusted solution in neurovascular embolization for over 25 years. IRVINE, Calif., Dec. 18, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) – Today, Johnson & Johnson MedTech, a leader in neurovascular care, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and chronic Subdural Hematoma (cSDH) as an

    12/18/25 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)

    RYBREVANT FASPRO™, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related reactions1-5 Approval builds on previously reported Phase 3 MARIPOSA data showing unmatched overall survival benefit of this chemotherapy-free regimen, projected to exceed four years6 HORSHAM, Pa., Dec. 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) administered therapy for patients with epidermal growth factor receptor (EGFR

    12/17/25 6:49:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    City of Manhattan, Kansas Selects Oracle Permitting and Licensing to Streamline Regulatory Services and Improve Citizen Experiences

    Modern cloud platform streamlining government workflows, enhancing self-service, ensuring compliance, and accelerating approvals for economic growth AUSTIN, Texas, Dec. 17, 2025 /PRNewswire/ -- The City of Manhattan, Kansas, has selected Oracle Permitting and Licensing (OPAL) to transform regulatory services, streamline review and approval processes, and foster local economic growth. The solution will provide residential and commercial developers with a modern, intuitive online application process that can guide each applicant through regulatory requirements to help speed permitting and project approvals in this support thriving community. 

    12/17/25 8:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairhead Rona Alison bought $112,258 worth of shares (480 units at $233.87), increasing direct ownership by 2% to 22,110 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    7/9/25 4:39:51 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Director Boskin Michael J bought $111,145 worth of shares (1,682 units at $66.08), increasing direct ownership by 2% to 92,458 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    3/21/25 8:43:30 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Director Moorman Charles W bought $947,913 worth of shares (5,500 units at $172.35) (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    2/14/25 4:41:16 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    SEC Filings

    View All

    SEC Form 144 filed by Oracle Corporation

    144 - ORACLE CORP (0001341439) (Subject)

    12/19/25 12:43:49 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-Q filed by Oracle Corporation

    10-Q - ORACLE CORP (0001341439) (Filer)

    12/11/25 4:07:47 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Oracle Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - ORACLE CORP (0001341439) (Filer)

    12/10/25 4:14:38 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Leadership Updates

    Live Leadership Updates

    View All

    Health Systems Simplify Secure Data Exchange with Oracle Health

    New Oracle Health Connection Hub delivers single, unified console to enable data sharing control, auditing, and governance so health systems can easily manage a broad range of interoperability services Early adopters see 50 percent reduction in processing times of Social Security Administration disability benefit claims AUSTIN, Texas, Oct. 9, 2025 /PRNewswire/ -- Oracle Health Connection Hub is now generally available for U.S. healthcare providers, enabling them to use a single console to more easily onboard, access, and manage preferences for Oracle Health interoperability solutions. The latest step in Oracle's strategy to increase interoperability and reduce friction between payers and pr

    10/9/25 9:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay

    12/15/25 4:27:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oracle Announces Fiscal Year 2026 Second Quarter Financial Results

    Q2 Remaining Performance Obligations $523 billion, up 438% in USDQ2 GAAP Earnings per Share up 91% to $2.10, Non-GAAP Earnings per Share up 54% to $2.26Q2 Total Revenue $16.1 billion, up 14% in USD and up 13% in constant currencyQ2 Cloud Revenue (IaaS plus SaaS) $8.0 billion, up 34% in USD and up 33% in constant currencyQ2 Cloud Infrastructure (IaaS) Revenue $4.1 billion, up 68% in USD and up 66% in constant currencyQ2 Cloud Application (SaaS) Revenue $3.9 billion, up 11% in both USD and constant currencyQ2 Fusion Cloud ERP (SaaS) Revenue $1.1 billion, up 18% in USD and up 17% in constant currencyQ2 NetSuite Cloud ERP (SaaS) Revenue $1.0 billion, up 13% in both USD and constant currencyAUSTI

    12/10/25 4:05:00 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Oracle Sets the Date for its Second Quarter Fiscal Year 2026 Earnings Announcement

    Earnings Results to be released on December 10, 2025, After the Close of the Market AUSTIN, Texas, Dec. 2, 2025 /PRNewswire/ -- Oracle Corporation today announced that its second quarter fiscal year 2026 results will be released on Wednesday, December 10th, after the close of the market.  Oracle will host a conference call and live webcast at 4:00 p.m. Central Time to discuss the financial results.  The live webcast will be available on the Oracle Investor Relations website at www.oracle.com/investor.  About Oracle Oracle offers integrated suites of applications plus secure, a

    12/2/25 8:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tactile Systems Technology Inc.

    SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/13/24 7:29:11 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tactile Systems Technology Inc.

    SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/13/24 5:04:27 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tactile Systems Technology Inc.

    SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/8/24 3:21:42 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care